Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(38%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_3
3
38%
Ph phase_2
4
50%

Phase Distribution

1

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Recruiting3
Completed2
unknown1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 24 (50.0%)
Phase 33 (37.5%)

Trials by Status

recruiting338%
unknown113%
withdrawn113%
terminated113%
completed225%

Recent Activity

3 active trials
Showing 5 of 8
recruitingphase_2

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

NCT07364786
recruitingphase_2

Antisecretory Factor In Severe Traumatic Brain Injury

NCT04117672
recruitingphase_2

Antisecretory Factor Glioblastoma Phase 2

NCT05669820
unknownphase_3

Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer

NCT06152471
completedphase_3

Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury

NCT03339505
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07364786Phase 2

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

Recruiting
NCT04117672Phase 2

Antisecretory Factor In Severe Traumatic Brain Injury

Recruiting
NCT05669820Phase 2

Antisecretory Factor Glioblastoma Phase 2

Recruiting
NCT06152471Phase 3

Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer

Unknown
NCT03339505Phase 3

Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury

Completed
NCT02731118Phase 3

Antisecretory Factor (AF) Effects on Intraocular-pressure

Terminated
NCT04116138Phase 1

Antisecretory Factor in Primary Glioblastoma 1

Completed
NCT03453749Phase 2

Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
8